[1] Lencioni R, Llovet JM.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1):52-60. [2] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21(2):143-168. [3] Zhong JH,Ke Y,Gong WF,et al.Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma[J]. Ann Surg,2014,260(2):329-340. [4] Hermann RE,Lonsdale D.Chemotherapy, radiotherapy, and hepatic lobectomy for hepatoblastoma in an infant:report of a survival[J]. Surgery,1970,68(2):383-388. [5] 汤钊猷,余业勤,周信达,等.不能切除肝癌的缩小疗法与序贯切除[J]. 肿瘤,1991,11(4):145-147. [6] Fan J,Tang ZY,Yu YQ,et al.Improved survival with resection after transcatheter arterial chemoembolization(TACE)for unresectable hepatocellular carcinoma[J]. Dig Surg,1998,15(6):674-678. [7] 赵海涛,桑新亭,芮静安,等.不能手术切除的晚期肝癌降期后切除疗效分析[J].中国医学科学院学报,2009,31(4):503-505. [8] Chen X, Lai L, Ye J, Li L.Downstaging therapies for unresectable hepatocellular carcinoma prior to hepatic resection:a systematic review and meta-analysis[J]. Front Oncol, 2021, 11:740762. [9] Finn RS,Ikeda M,Zhu AX,et al.Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol,2020,38(26):2960-2970. [10] Finn RS, Qin S,Ikeda M,et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med,2020, 382(20):1894-1905. [11] 张雯雯,胡丙洋,韩骏,等. PD-1抑制剂与多靶点酪氨酸激酶抑制剂联合方案用于进展期肝癌转化治疗研究的初步报告[J].中华肝胆外科杂志,2020,26(12):947-948. [12] Zhu XD,Huang C,Shen YH,et al.Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations[J]. Liver Cancer, 2021, 10(4):320-329. [13] 韩福洲,钱红纲,胡越,等. 初始不可切除肝癌转化治疗后行肝切除术九例临床特征分析[J]. 肝胆胰外科杂志,2021,33(12):715-720. [14] 曹俊宁,张雯雯,赵海涛,等. 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021版)[J]. 肝癌电子杂志,2021,8(2):6-15. [15] Chang X, Lu X, Guo J, et al.Interventional therapy combined with immune checkpoint inhibitors:Emerging opportunities for cancer treatment in the era of immunotherapy[J]. Cancer Treat Rev, 2019, 74:49-60. [16] Zheng L, Fang S, Wu F, et al.Efficacy and safety of tace combined with sorafenib plus immune checkpoint inhibitors for the treatment of intermediate and advanced tace-refractory hepatocellular carcinoma:a retrospective study[J]. Front Mol Biosci, 2021, 7:609322. [17] He MK, Liang RB, Zhao Y, et al.Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapyversuslenvatinib alone for advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2021,13:17588359211002720. [18] 张泽,曹银彪,万涛,等. 转化序贯外科手术方案治疗不可手术切除肝细胞癌的安全性与有效性分析[J].中华肝胆外科杂志,2022,28(1):15-20. [19] 韦滔,唐置鸿,韦猛,等. TACE联合TKI及PD-1抑制剂在不可切除肝细胞癌患者转化治疗中的疗效[J]. 中国癌症防治杂志,2021,13(4):413-419. [20] Jin S, Fu Q, Wuyun G, et al.Management of post-hepatectomy complications[J]. World J Gastroenterol, 2013, 19(44):7983-7991. [21] Russell MC.Complications Following Hepatectomy[J]. Surg Oncol Clin N Am, 2015, 24(1):73-96. [22] Cho JY, Han HS, Choi Y, et al.Association of remnant liver ischemia with early recurrence and poor survival after liver resection in patients with hepatocellular carcinoma[J]. JAMA Surg,2017,152(4):386-392. [23] 夏勇,杨田,王葵. 肝细胞癌肝切除术后复发预防和治疗中国专家共识(2020版)[J].中国实用外科杂志,2021,41(1):20-30. |